ProShare Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

ProShare Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-63,851	Closed	-$2.92M	–	1802
2017 Q4	$2.92M	Buy	63,851 +2,043	+3%	+$102K	0.02%	533
2017 Q3	$2.77M	Buy	61,808 +5,754	+10%	+$196K	0.03%	495
2017 Q2	$1.68M	Sell	56,054 -2,075	-4%	-$51.2K	0.02%	601
2017 Q1	$1.29M	Sell	58,129 -12,907	-18%	-$277K	0.01%	669
2016 Q4	$1.34M	Buy	71,036 +1,852	+3%	+$45.3K	0.01%	660
2016 Q3	$2.08M	Sell	69,184 -11,828	-15%	-$368K	0.03%	480
2016 Q2	$3.11M	Buy	81,012 +2,462	+3%	+$102K	0.04%	345
2016 Q1	$2.99M	Sell	78,550 -5,000	-6%	-$174K	0.04%	344
2015 Q4	$3.67M	Buy	+83,550	New	+$4.14M	0.04%	352

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

ProShare Advisors's JUNO Position: Q1 2018 in Review

ProShare Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 63,851 shares — an estimated $2.92M sold.

ProShare Advisors first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $3.67M in Q4 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

ProShare Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
ProShare Advisors sold 63,851 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $2.92M.
ProShare Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
ProShare Advisors's Juno Therapeutics, Inc. position peaked at $3.67M in Q4 2015.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on ProShare Advisors's 13F filing for Q1 2018, filed 14 May 2018.